ENDPOINTS

Merck’s PAH drug slashed risk of serious events in halted trial

New data unveiled Monday showed that Merck’s Winrevair can significantly cut the risk of death, lung transplantation and hospitalization in patients with a rare form of high blood pressure in the ...

Mar 31, 2025 - 17:25
 0
Merck’s PAH drug slashed risk of serious events in halted trial
New data unveiled Monday showed that Merck’s Winrevair can significantly cut the risk of death, lung transplantation and hospitalization in patients with a rare form of high blood pressure in the ...
Read More

Tags:

Previous Article

Why 50-Degree-F Days Feel Warmer in Spring Than in Fall

Next Article

WELL Health to acquire HEALWELL AI alongside Orion Health deal

Related Posts

Merck KGaA confirms interest in acquiring cancer biotech SpringWorks

Merck KGaA confirms interest in acquiring cancer biotec...

Feb 10, 2025  0

Arrowhead reveals small batch of open-label data for 'non-core' kidney drug

Arrowhead reveals small batch of open-label data for 'n...

Mar 10, 2025  0

‘It’ll be a challenge’: BIO chief Crowley addresses seismic FDA overhaul

‘It’ll be a challenge’: BIO chief Crowley addresses sei...

Apr 1, 2025  0